<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">van de Werf, Frans</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dabigatran Inferior to Warfarin in Patients with Mechanical Heart Valves</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Preclinical studies in porcine mechanical heart valve models suggested that dabigatran may effectively prevent valve thrombosis [Schomburg JL et al. J Invest Surg 2012]. These results led to A Randomized, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients After Heart Valve Replacement [RE-ALIGN; Eikelboom JW et al. N Engl J Med 2013]. The aim of the RE-ALIGN trial was to evaluate a dosing algorithm of dabigatran based on the RE-LY study to prevent thromboembolic complications in patients with mechanical heart valve replacement.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>